No Definite Link Between Yoga, Quality of Life in Patients With Colorectal Cancer
the Cancer Therapy Advisor take:
Given the trial’s high attrition rate and low intervention adherence, no definite conclusions can be made between yoga and the health-related quality of life in patients with colorectal cancer, according to an article published online in the journal Psycho-Oncology.
Participants in this study included 54 patients (mean age 68.3 ± 9.7 years) who were randomly assigned to a 10-week yoga intervention (90 minutes once weekly; mean attendance 5.3 ± 4.0 yoga classes) or a waitlist control group. Twenty-seven patients were randomized to both the yoga and control group (attrition rate 22.2% and 18.5%, respectively).
Results showed no significant differences in the Functional Assessment of Cancer Therapy—Colorectal (FACT-C) total score between the two groups, which measured disease-specific quality of life.
However, differences were observed between the two groups’ emotional well-being at week 22 (∆ = 1.59; 95% CI: 0.27, 2.90; P= 0.019), sleep disturbances at week 22 (∆ = −1.08; 95% CI: −2.13, −0.03; P=0.043), anxiety at week 10 (∆ = −1.14; 95% CI: −2.20, −0.09; P=0.043), and depression at week 10 (∆ = −1.34; 95% CI: −2.61, −0.8; P=0.038).
Furthermore, no serious adverse events were observed in the yoga intervention cohort, while liver metastases occurred in one patient in the control group.
No definite conclusions can be made between yoga and the health-related quality of life in patients with colorectal cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy
- Triclosan and Cancer Risk: Is There a Link?
- Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma
- Chemotherapy May Improve Survival Outcomes in High-Risk Soft-Tissue Sarcoma
- Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer